Literature DB >> 8388383

N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.

L B Møller1, J Pöllänen, E Rønne, N Pedersen, F Blasi.   

Abstract

Variations in glycosylation exist among urokinase plasminogen activator receptors (u-PARs) from different cell types. We have studied the functional role of N-linked carbohydrate within the ligand-binding domain of u-PAR. Treatment with glycosidases demonstrated that all the N-linked carbohydrates on u-PAR are complex-type oligosaccharides. Substitution of a single Asn (Asn52) to Gln by means of site-directed mutagenesis led to an active receptor mutant with a ligand-binding domain devoid of carbohydrate. The cellular distribution, the glycosyl-phosphatidylinositol anchoring, and the conformational stability after solubilization were unaffected by this single substitution. However, ligand binding analysis demonstrated a 4- 5-fold decrease in affinity as compared with the wild type receptor. Two different strategies were used in order to obtain a u-PAR type completely devoid of N-linked carbohydrates. 1) Tunicamycin treatment of wild type u-PAR-expressing cells. 2) Mutation of all glycosylation sites (Hu-PARN5-mut). In neither case, unglycosylated receptors with ligand binding activity were identified. However, immunofluorescence studies demonstrated that the Hu-PARN5-mut was retained inside the cells in the endoplasmic reticulum. The same result was found for Hu-PARN4-mut, where only the glycosylation sites outside the binding domain were mutated. These results demonstrate that some extent of glycosylation of u-PAR is necessary for cellular transport and for molecular maturation events leading to ligand binding activity. Glycosylation of the binding domain per se affects only the affinity of the receptor. The positive modulation of the Asn52 carbohydrate side chain on ligand affinity suggests that the u-PAR glycosylation variants observed in various cell types may have different functional roles.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388383

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Isolation and characterization of cell lines with reduced urokinase binding.

Authors:  H K Lau; J M Teitel; M Kim
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

5.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

6.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

7.  Glycosylation of Asn-76 in mouse GPIHBP1 is critical for its appearance on the cell surface and the binding of chylomicrons and lipoprotein lipase.

Authors:  Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Robert O Ryan; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-03-13       Impact factor: 5.922

8.  Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.

Authors:  Sanaz Memarzadeh; Katherine R Kozak; Lisbeth Chang; Sathima Natarajan; Peter Shintaku; Srinivasa T Reddy; Robin Farias-Eisner; Sanaz Memarzedeh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-18       Impact factor: 11.205

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Characterization of the five novel Ly-6 superfamily members encoded in the MHC, and detection of cells expressing their potential ligands.

Authors:  Meera Mallya; R Duncan Campbell; Begoña Aguado
Journal:  Protein Sci       Date:  2006-10       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.